Preview

Научно-практическая ревматология

Расширенный поиск

Информативно ли партнерское участие больных в фармакологическом надзоре?

https://doi.org/10.14412/1995-4484-2017-449-451

Полный текст:

Аннотация

Обсуждается целесообразность и возможность спонтанных сообщений больных о неблагоприятных реакциях на лекарственные препараты.

Об авторе

Ю. В. Муравьев
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия

115522 Москва, Каширское шоссе, 34А



Список литературы

1. Wooten JM. Adverse drug reactions: part I. South Med J. 2010;103(10):1025-8. doi: 10.1097/SMJ.0b013e3181f0c866

2. WHO Technical Report. 1972;498.

3. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis and management. Lancet. 2000;356:1255-9. doi: 10.1016/S0140-6736(00)02799-9

4. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279(15):1200-5. doi: 10.1001/jama.279.15.1200

5. Watson R. New EU drug safety committee ends national reporting of drug reactions. BMJ. 2012;345:e4690. doi: 10.1136/bmj.e4690

6. Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother. 2008;42(7):1017-25. doi: 10.1345/aph.1L037

7. Bordet R, Gautier S, Le Louet H, et al. Analysis of the direct cost of adverse drug reactions in hospitalized patients. Eur J Clin Pharmacol. 2001;56(12):935-41. doi: 10.1007/s002280000260

8. Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA. 1995;274(1):29-34. doi: 10.1001/jama.1995.03530010043033

9. Oshikoya KA, Awobusuyi JO. Perceptions of doctors to adverse drug reaction reporting in a teaching hospital in Lagos, Nigeria. BMC Clin Pharmacol. 2009;9:14. doi: 10.1186/1472-6904-9-14

10. Aagaard L, Nielsen LH, Hansen EH. Consumer reporting of adverse drug reactions: a retrospective analysis of the Danish adverse drug reaction database from 2004 to 2006. Drug Saf. 2009;32(11):1067-74. doi: 10.2165/11316680-000000000-00000

11. Van Puijenbroek E, Diemont W, van Grootheest K. Application of quantitative signal detection in the Dutch spontaneous reporting system for adverse drug reactions. Drug Saf. 2003;26(5):293-301. doi: 10.2165/00002018-200326050-00001

12. Stricker BH, Psaty BM. Detection, verification, and quantification of adverse drug reactions. BMJ. 2004;329(7456):44-7. doi: 10.1136/bmj.329.7456.44

13. Sharrar RG, Dieck GS. Monitoring product safety in the postmarketing environment. Ther Adv Drug Saf. 2013;4(5):211-9. doi: 10.1177/2042098613490780

14. Herdeiro MT, Figueiras A, Polonia J, Gestal-Otero J. Influence of pharmacists' attitudes on adverse drug reaction reporting. Drug Saf. 2006;29(4):331-40. doi: 10.2165/00002018- 200629040-00004

15. Olsson S. The role of the WHO programme on International Drug Monitoring in coordinating worldwide drug safety efforts. Drug Saf. 1998;19:1-10. doi: 10.2165/00002018- 199819010-00001

16. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006,29:385-96. doi: 10.2165/00002018-200629050-00003

17. Biagi C, Montanaro N, Buccellato E, et al. Underreporting in pharmacovigilance: an intervention for Italian GPs (Emilia- Romagna region). Eur J Clin Pharmacol. 2013;69(2):237- 44. doi: 10.1007/s00228-012-1321-7

18. Alvarez-Requejo A, Carvajal A, Begaud B, et al. Under-reporting of adverse drug reactions. Estimate based on a spontaneous reporting scheme and a sentinel system. Eur J Clin Pharmacol. 1998,54:483-8. doi: 10.1007/s002280050498

19. Meyboom RH, Egberts AC, Gribnau FW, Hekster YA. Pharmacovigilance in perspective. Drug Safety. 1999;21(6):429-47. doi: 10.2165/00002018-199921060-00001

20. Inman WH. Attitudes to adverse drug reaction reporting. Br J Clin Pharmacol. 1996;41:434-5.

21. Backstrom M, Mjorndal T, Dahlqvist R. Under-reporting of serious adverse drug reactions in Sweden. Pharmacoepidemiol Drug Saf. 2004;13:483-7. doi: 10.1002/pds.962

22. Herxheimer A, Crombag R, Alves TL. Patients reported adverse drug reactions: what's happening in Europe. Assist Inferm Ric. 2011;30(1):42-7.

23. Mitchell AS, Henry DA, Sanson-Fisher R, O'Connell DL. Patients as a direct source of information on adverse drug reactions. BMJ (Clinical research ed). 1988;297(6653):891-3. doi: 10.1136/bmj.297.6653.891

24. Hazell L, Cornelius V, Hannaford P, et al. How do patients contribute to signal detection? A retrospective analysis of spontaneous reporting of adverse drug reactions in the UK's Yellow Card Scheme. Drug Saf. 2013;36(3):199-206. doi: 10.1007/s40264-013-0021-2

25. Blenkinsopp A, Wilkie P, Wang M, Routledge PA. Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br J Clin Pharmacol. 2006;63:148-56. doi: 10.1111/j.1365-2125.2006.02746.x

26. Van Grootheest K, de Graafde L, de Jong-van den Berg LT. Consumer adverse drug reaction reporting: a new step in pharmacovigilance? Drug Saf Int J Med Toxicol Drug Exp. 2003;26(4):211- 7. doi: 10.2165/00002018-200326040-00001

27. Aagaard L, Hansen EH. Consumers' reports of suspected adverse drug reactions volunteered to a consumer magazine. Br J Clin Pharmacol. 2010;69(3):317-8. doi: 10.1111/j.1365-2125.2009.03584.x

28. Aronson J. Risk perception in drug therapy. Br J Clin Pharmacol. 2006;62(2):135-7. doi: 10.1111/j.1365-2125.2006.02739_1.x

29. Bongard V, Menard-Tache S, Bagheri H, et al. Perception of the risk of adverse drug reactions: ifferencesbetween health professionals and non health professionals. Br J Clin Pharmacol. 2002;54(4):433-06. doi: 10.1046/j.1365-2125.2002.01674.x

30. Matos C, van Hunsel F, Joaquim J. Are consumers ready to take part in the Pharmacovigilance System? – a Portuguese preliminary study concerning ADR reporting. Eur J Clin Pharmacol. 2015;71(7):883-90. doi: 10.1007/s00228-015-1867-2

31. World Health Organization website. http://apps.who.int/ medicinedocs/fr/d/Jh1465e/4.html. Accessed 20 Sept 2013.

32. Egberts TC, Smulders M, de Koning FH, et al. Can adverse drug reactions be detected earlier? A comparison of reports by patients and professionals. BMJ. 1996;313(7056):530-1. doi: 10.1136/bmj.313.7056.530

33. Van Hunsel F, Talsma A, van Puijenbroek E, et al. The proportion of patient reports of suspected ADRs to signal detection in the Netherlands: case-control study. Pharmacoepidemiol Drug Saf. 2011;20(3):286-91. doi: 10.1002/pds.2092

34. Van Hunsel F, Passier A, van Grootheest AC. Comparing patients' and healthcare professionals' ADR reports after media attention: the broadcast of a Dutch television programme about the benefits and risks of statins as an example. Br J Clin Pharmacol. 2009;67(5):558-64. doi: 10.1111/j.1365-2125.2009.03400.x

35. Inch J, Watson MC, Anakwe-Umeh S. Patient versus healthcare professional spontaneous adverse drug reaction reporting: a systematic review. Drug Saf. 2012;35(10):807-18. doi: 10.1007/BF03261977

36. Margraff F, Bertram D. Adverse drug reaction reporting by patients: an overview of fifty countries. Drug Saf. 2014 Jun;37(6):409-19. doi: 10.1007/s40264-014-0162-y


Для цитирования:


Муравьев Ю.В. Информативно ли партнерское участие больных в фармакологическом надзоре? Научно-практическая ревматология. 2017;55(4):449-451. https://doi.org/10.14412/1995-4484-2017-449-451

For citation:


Muravyev Yu.V. IS THE PATIENT PARTNERSHIP INFORMATIVE IN PHARMACOVIGILANCE? Rheumatology Science and Practice. 2017;55(4):449-451. (In Russ.) https://doi.org/10.14412/1995-4484-2017-449-451

Просмотров: 232


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)